<DOC>
	<DOCNO>NCT01632995</DOCNO>
	<brief_summary>This study assess uptake , acceptability , safety , feasibility HIV pre-exposure prophylaxis ( PrEP ) , consist once-daily fixed-dose combination tablet emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) , administer sexually transmitted disease ( STD ) clinic community health center United States .</brief_summary>
	<brief_title>Assessment Pre-Exposure Prophylaxis ( PrEP ) Administered Sexually Transmitted Disease ( STD ) Clinics</brief_title>
	<detailed_description>A previous study ( iPrEx ) show daily PrEP FTC/TDF provide comprehensive package prevention service effective prevent HIV infection among men sex men ( MSM ) . The PrEP administer study give context research setting/controlled trial , important evaluate acceptability , sustainability , safety PrEP `` real world '' set . This study evaluate PrEP administer HIV-uninfected MSM transgender female two STD clinic one community health center United States . Each participant receive PrEP 1 year 8 study visit . PrEP consist one fixed-dose FTC/TDF combination tablet orally day . All participant study visit screen , enrollment , 4 week enrollment ; participant continue visit Weeks 12 , 24 , 36 , 48 , 52 seroconvert . Participants seroconvert discontinue PrEP post-drug discontinuation visit 4 week discontinue PrEP . At visit , participant undergo blood , urine , hair sample collection ; give medical history ; undergo physical exam ; receive risk-reduction counseling condom ; undergo test HIV STDs ; receive study drug ; undergo pill count adherence assessment ( follow-up visit ) . For participant stop take study drug remain study , urine , blood , hair sample collect 12-week follow-up visit stop procedure complete lab abnormality require additional follow-up . Participants also answer questionnaire screen , 12-week visit , study exit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sexually Transmitted Diseases</mesh_term>
	<criteria>Must either man sex men transgender female Male sex ( birth ) Willing able provide write informed consent HIV1 uninfected , define negative rapid HIV antibody test screen visit enrollment negative 4th generation antibody/antigen test screen No laboratory evidence detectable HIV viral load ( San Francisco site ) Evidence risk acquire HIV1 infection include one following : ( 1 ) Condomless anal sex two male transgender female sex partner last 12 month ; ( 2 ) two episode anal sex least one HIVpositive partner last 12 month ; ( 3 ) sex male transgender female partner follow STDs diagnose last 12 month screen : syphilis , rectal gonorrhea , rectal chlamydia . Able provide street address residence phone number two personal contact would know whereabouts period demonstration project Adequate renal function : creatinine clearance 60 ml/min great estimate CockcroftGault equation within 45 day enrollment A urine dipstick negative trace result protein within 45 day enrollment Fluent English Spanish Signs symptom acute HIV infection Previously diagnose active serious infection include active tuberculosis infection osteomyelitis infection require parenteral antibiotic therapy ( STDs require intramuscular injection antibiotic ) ; active clinically significant medical problem include poorly control cardiac disease ( e.g. , symptoms ischemia congestive heart failure ) previously diagnose malignancy expect require treatment Hepatitis B surface antigen ( HBsAg ) positive History pathological bone fracture relate trauma Receiving ongoing therapy following : investigational antiretroviral agent ( PEP allow describe protocol ) , interferon ( alpha , beta , gamma ) interleukin ( e.g. , IL2 ) therapy , agent significant nephrotoxic potential , agent may inhibit compete elimination via active renal tubular secretion ( e.g. , probenecid ) , and/or investigational agent Concomitant participation clinical trial use investigational agent , include placebocontrolled clinical trial use agent At enrollment , condition , base opinion investigator designee , would preclude provision informed consent ; make participation project unsafe ; complicate interpretation outcome data ; otherwise interfere achieve project objective</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>